A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Coly-Mycin Pharmacology, Pharmacokinetics, Studies, Metabolism - Sterile Colistimethate Sodium
Coly-Mycin Pharmacology, Pharmacokinetics, Studies, Metabolism - Sterile Colistimethate Sodium
CLINICAL PHARMACOLOGY
Typical serum and urine levels following a single 150 mg dose of
Coly-Mycin M Parenteral IM or IV in normal adult subjects are shown in
Figure 1.
Higher serum levels were obtained at 10 minutes following IV
administration. Serum concentration declined with a half-life of 2-3 hours
following either intravenous or intramuscular administration in adults and
in the pediatric population, including premature infants.
Average urine levels ranged from about 270 mcg/mL at 2 hours to about 15 mcg/mL
at 8 hours after intravenous administration and from 200 to about 25 mcg/mL
during a similar period following intramuscular administration.
Microbiology: Colistimethate sodium is a surface active
agent which penetrates into and disrupts the bacterial cell membrane.
It has been shown to have bactericidal activity against most strains of
the following microorganisms, both in vitro and in clinical infections
as described in the INDICATIONS
AND USAGE section:
Aerobic gram-negative microorganisms:
Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae , and
Pseudomonas aeruginosa
Susceptibility Tests: Colistimethate sodium is no longer
listed as an antimicrobial for routine testing and reporting by clinical microbiology
top
